Objective. Efficacy of TNF inhibitors in the treatment of RA assessed in randomized controlled trials (RCTs) may not be fully comparable to routine care owing to the stringent inclusion criteria. The objective of this study was to observe the effectiveness of TNF inhibitors in real-world patients and assess the patients' potential eligibility for the RCTs.
Introduction
According to the Finnish current care guidelines updated in 2015, the treatment of RA is initiated with a combination of MTX, SSZ, HCQ and low-dose glucocorticoid [1] . In case of insufficient treatment response or intolerance to conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs) may be added to the treatment. Nevertheless, it is still considered beneficial to continue using MTX concomitantly with a bDMARD owing to better effectiveness [2] .
Most of the information on the efficacy and safety of biologic treatments has been derived from randomized controlled trials (RCTs). Although RCTs can provide high-quality information, their stringent inclusion criteria for patients and often brief follow-up times limit the generalizability of the results to routine care [3] . Observational trials based on either retrospective, administrative healthcare data or purpose-collected prospective data can provide information based on the true use of medicines among real patients. However, observational studies are prone to various types of biases, which reflect the lack of randomization and the quality and completeness of the data.
The proportion of TNF-inhibitor users achieving ACR50 and moderate EULAR responses and DAS28 remission at 612 months after treatment onset has ranged from 21 to 66, 55 to 90 and 7 to 66%, depending on the patients' baseline disease activity, concomitant csDMARD use and the trial protocol [4, 5] . Previous studies have shown that 2280% of RA patients treated with TNF inhibitors in routine clinical practice would have been eligible for RCTs and that the observed treatment effectiveness was better among the eligible patients compared with those not eligible [3, 6] . Results based on previous observational studies are very heterogeneous, with the fraction of EULAR good and moderate responders on the first course of bDMARD therapy ranging from 11 to 53 and 50 to 93%, respectively [3, 611] . Even greater variation, 450%, is present in the fraction of patients achieving DAS28 remission.
The objective of this study was to assess the effectiveness of TNF inhibitors in routine clinical practice and study the effect of concomitant csDMARD therapy on it. As a secondary outcome, we compared the baseline characteristics of TNF-inhibitor users with the inclusion criteria of RCTs to find out how large a proportion of Finnish patients treated in routine clinical practice would have been eligible for the RCTs and whether there is a difference in the effectiveness of TNF inhibitors between eligible and noneligible patients.
Methods
Patients were identified from National Register for Biologic Treatment in Finland (ROB-FIN), which is a longitudinal cohort study comprising data on patients diagnosed with rheumatic diseases treated with bDMARDs in routine clinical practice. Data are collected on routine care visits to rheumatologists, which usually take place 3 and 6 months after the onset of TNF therapy and biannually thereafter. RA patients having started TNF-inhibitor therapy as their first, second or third biologic treatment between 2004 and 2014 and from whom a valid baseline visit was available were included in this study. Additional data on the patients' co-morbidities and hospital treatment were retrieved from the Finnish Hospital Discharge Register and Finnish Cancer Register.
The results are reported as medians with their respective interquartile ranges (IQRs) or percentages. Differences in baseline patient characteristics and disease activity between different TNF inhibitors were tested using the 2 test, MannWhitney U-test or KruskalWallis test where appropriate.
The effectiveness of TNF inhibitors was measured using either ACR or EULAR response criteria, which were estimated at time points of 6, 12 and 24 months after the treatment onset using linear interpolation. LUNDEX adjustment, in which the fraction of responders is multiplied by the fraction of patients remaining in the study, was used to account for the fraction of patients discontinuing the treatment or lost to follow-up [12] . Ordinal logistic regression on reaching moderate or good EULAR response was used to compare different TNF inhibitors with one another while accounting for the differences in baseline characteristics, as well as to evaluate the effect of concomitant csDMARDs on the treatment effectiveness. The best models in terms of Akaike information criteria were used to adjust the ordinal logistic regression analyses. Effect modification was explored by including interaction terms in the model. The effect of patient attrition was explored in ordinal logistic regression by treating the patients having discontinued the treatment as nonresponders, which is equivalent to LUNDEX adjustment at group level.
RCTs of at least 6 months of duration, in which the efficacy of TNF inhibitors had been compared with placebo, csDMARDs or another bDMARD, were identified from the two systematic reviews informing the EULAR guidelines for management of RA [4, 5] . RCTs that excluded patients with prior MTX treatment were not included in this study. We assumed that all TNF-inhibitor users included in ROB-FIN had previously used MTX in accordance with Finnish treatment guidelines, although we did not have data on patients' medication history prior to TNF-inhibitor treatment onset to verify this. Information on the inclusion criteria and efficacy results was retrieved from the original publications of the selected RCTs and clinicaltrials.gov. The inclusion criteria were then used to stratify the patients identified from ROB-FIN using the same TNF inhibitor into two groups based on their eligibility for the given RCT. Not all criteria could be adapted fully, either because we lacked the data do so or because they were too vaguely reported. Also, we chose not to use the patients' concomitant csDMARD therapy at baseline as inclusion criteria. Furthermore, the number of swollen and tender joints in our data was measured on a 54/53 index as opposed to 66/68 index in most RCTs (supplementary Fig. S1 , available at Rheumatology Online). Hence, we multiplied the number of tender and swollen joints in our data by 1.22 and 1.28, respectively, and rounded them to the nearest integer. However, this correction was used only in the context of the patients' compatibility with the inclusion criteria, whereas joint indices were left unaltered for all other purposes.
The treatment responses of eligible and non-eligible patients were compared using Fisher's exact test with Bonferroni correction for multiple comparisons and pooled using a random-effects model with MantelHaenszel method. Baseline differences in patient characteristics, disease activity and the use of csDMARDs were compared between eligible and non-eligible patients.
Results are reported as medians with their respective IQR, percentages and proportional odds ratios (pORs) with their respective 95% CI. Missing data were imputed by multiple imputation with predictive mean matching and 20 imputed data sets. The level of statistical significance was set at 0.05. Data management and statistical analyses were carried out using R software version 3.11 (R foundation for statistical computing, Vienna, Austria). This study was approved by the Helsinki and Uusimaa Hospital District coordinating ethical committee and the National Institute for Health and Welfare. Patient consent was not required because patient data were taken from existing registries and hospital records.
Results

Patients and follow-up
Of the 4165 TNF-inhibitor treatment periods identified from ROB-FIN, 739 and 934 were excluded owing to the treatment not being started between 2004 and 2014 and the lack of reliable baseline measurement, respectively. In total, 2053 patients were included, of whom 1682, 633 and 177 used TNF inhibitors as their first, second or third bDMARD, respectively.
Included patients were predominantly female (74%), and the median age at the baseline of the first and second or third bDMARD was 55 (IQR: 4562) and 56 years (IQR: 4763), respectively (Table 1) . Adalimumab and etanercept were the most frequently used TNF inhibitors, covering 80% of all TNF-inhibitor treatments in this study. MTX, SSZ, HCQ and glucocorticoid were used as a co-therapy by 56, 26, 33 and 72% of the patients at the baseline of the TNF-inhibitor treatment period, respectively. Thirteen per cent of the TNF-inhibitor treatments were initiated as monotherapy without concomitant csDMARDs.
At the baseline of the first bDMARD, there were numerous statistically significant differences in baseline characteristics of the included patients between the users of different TNF inhibitors and concomitant csDMARDs (data not shown). Patients excluded from the study owing to the lack of reliable baseline measurement, that is, whose treatment had been initiated before the first visit recorded in our study, had significantly lower DAS28 score (3.0 vs 4.1, P < 0.001) at their first visit compared with the included patients.
Of the patients using TNF inhibitors as their first bDMARD, 65% remained on the treatment until 6 months, 22% discontinued the treatment and possibly switched to using another bDMARD, whereas the remaining 14% of the patients were lost to follow-up. Similar percentages for the patients' second or third bDMARD were 58, 25 and 17%, respectively. The respective proportions of patients remaining on treatment at 12 and 24 months were 51 and 36% among the users of first bDMARD and 47 and 36% among the users of second or third bDMARD. The amount of missing data varied from 0 to 27% across the variables in the data set.
Treatment effectiveness
EULAR moderate and good treatment responses at 6 months were achieved by 69 and 40% of the users of the first bDMARD, respectively, whereas similar percentages after LUNDEX adjustment were 44 and 26%, respectively ( Fig. 1 ). ACR20, ACR50 and ACR70 responses were reached by 49, 27 and 13% of the patients, respectively, and after LUNDEX adjustment by 32, 17 and 8.5%, respectively. DAS28 remission criteria were fulfilled by 47 and 30% of the patients with and without LUNDEX adjustment, respectively.
The highest EULAR and ACR response rates on the patients' first bDMARD at 6 months were observed with certolizumab pegol, although this was no longer the case after LUNDEX adjustment (supplementary Fig. S2 , available at Rheumatology Online). Golimumab, in contrast, was associated with the largest proportion of patients in remission at 6 months. However, there were no statistically significant differences between individual TNF inhibitors in unadjusted response or remission rates. The adjusted ordinal logistic regression model revealed no statistically significant differences between individual TNF inhibitors (Fig. 2) . The variables included in the final regression model with their respective pORs are reported in supplementary Tables S1 and S2, available at Rheumatology Online.
The patients not using any concomitant csDMARDs at baseline of the first TNF-inhibitor treatment had the lowest EULAR and ACR treatment responses at 6 months with and without LUNDEX adjustment (supplementary Fig. S3 , available at Rheumatology Online). Six months after the TNF-inhibitor treatment onset, 41% of the patients on biologic monotherapy were in DAS28 remission (24% with LUNDEX adjustment), whereas remission was reached by 51% (LUNDEX 35%) and 39% (LUNDEX 24%) of the patients using concomitant csDMARDs including or excluding MTX, respectively. The highest ACR and EULAR responses were also reached by patients using concomitant MTX. In adjusted ordinal logistic regression analysis of reaching EULAR moderate or good response, co-therapy with MTX had a pOR of 1.5 (95% CI: 1.0, 2.3). After accounting for the patients having discontinued the treatment or lost to follow-up, the corresponding pOR was 1.6 (95% CI: 1.1, 2.2). In the unadjusted model, glucocorticoid use was associated with reaching EULAR response (pOR 1.4, 95% CI: 1.1, 1.8), but this was not the www.rheumatology.oxfordjournals.org case after adjustment for confounding (pOR 1.1, 95% CI: 0.79, 1.4). No statistically significant effect modification between the medication modalities was found.
The treatment response and remission rates for the second and third bDMARD users were lower compared with the first bDMARD therapy, because only 32, 21 and 26% of the patients reached LUNDEX-adjusted moderate EULAR and ACR20 responses and DAS28 remission criteria, respectively, at 6 months (supplementary Fig. S4 , available at Rheumatology Online). We were unable to find statistically significant associations in logistic regression between the TNF-inhibitor, csDMARD or glucocorticoid therapy and EULAR treatment response at 6 months.
Eligibility for RCTs
We identified 27 RCTs fulfilling the inclusion criteria for our study, of which 13 and 2 limited inclusion to biologic-naïve patients and prior TNF-inhibitor users, respectively [1339] . The remaining 12 RCTs imposed some restrictions to prior biologics or did not state whether prior biologics were allowed. Prior biologic therapy was not, however, used as an inclusion criterion but rather to select the appropriate subset of patients from ROB-FIN for each of the ensuing comparisons. The inclusion criteria of the included RCTs are listed in supplementary Fig. S3 , available at Rheumatology Online. The fraction of patients identified from ROB-FIN eligible for the included RCTs ranged from 7.6 to 44% (Table 2) . Inclusion was most often rejected because of insufficient disease activity at baseline, but only rarely because of co-morbidities or a history with certain medical conditions. Efficacy was reported as ACR50 and EULAR responses at 6 or 12 months after treatment onset in 24 and 6 trials, respectively. Additionally, the fraction of patients in DAS28 remission was reported in 12 trials. Figure 3 shows the ACR50 responses measured in RCTs at 6 or 12 months after TNF-inhibitor treatment onset and the corresponding responses based on ROB-FIN for patients using the same TNF inhibitor either eligible or not eligible for the given RCT. In 8 out of 24 comparisons between eligible and non-eligible patients, the former had a statistically significantly better ACR50 treatment response. Pooled results for reaching the ACR50 and moderate EULAR responses between eligible and non-eligible patients showed risk ratios of 1.7 (95% CI: 1.5, 1.9) and 1.3 (95% CI: 1.2, 1.4), respectively, in favour of the eligible ones. However, the non-eligible patients reached DAS28 remission more often compared with the eligible patients, with a risk ratio of 0.58 (95% CI: 0.42, 0.79). This implies that with the treatment aim of remission, TNF-inhibitor therapy should not be limited to RCT-eligible patients only, although the treatment costs should also be kept in mind. Pooled risk ratios for achieving ACR50 between RCTs and eligible patients, and between RCTs and non-eligible patients were 0.91 (95% CI: 0.78, 1.1) and 1.6 (95% CI: 1.4, 1.9), respectively. Baseline differences in disease activity and concomitant csDMARD therapy were compared between eligible and
FIG. 1 Treatment responses and remission rates of TNF inhibitors as patients' first biologic DMARD
Data given at 3, 6, 12 and 24 months after treatment onset. bDMARD: biologic DMARD; ROB-FIN: National Register for Biologic Treatment in Finland.
www.rheumatology.oxfordjournals.org non-eligible patients. In 25 out of 27 comparisons, the eligible patients had a statistically significantly higher DAS28 score at baseline compared with the non-eligible patients. In 15 comparisons, erosions in hands and feet were more prevalent among the eligible patients. The eligible patients were older and had a longer time from diagnosis in eight and seven comparisons, respectively. In the majority of the comparisons, there were no statistically significant differences in the csDMARD used; however, in seven comparisons a larger fraction of non-eligible patients were using MTX, whereas in another two comparisons the situation was reversed. The percentage of patients on biologic monotherapy was similar across all comparisons.
Discussion
According to our results, TNF inhibitors are equipotent in routine clinical practice, but concomitant treatment with MTX improves the treatment response. Our study also showed that 7.644% of the patients included in the ROB-FIN register and treated with TNF inhibitors in routine clinical practice in Finland would have been potentially eligible for the RCTs conducted during the past 15 years and that the eligibility predicted better treatment responses.
Previous studies have also shown that TNF inhibitors are more effective in combination with MTX than as monotherapy [2] . The present study confirmed the benefit of using concomitant MTX therapy alongside TNF-inhibitor treatment in routine clinical practice. Despite bDMARD monotherapy being inferior to combination therapy, 61 and 36% of the patients starting on biologic monotherapy were still able to reach moderate EULAR response and DAS28 remission, respectively, without accounting for the patient attrition. This study did not include tocilizumab, which may be more effective as monotherapy in comparison with TNF inhibitors [16] . Co-therapy with csDMARDs not including MTX did not appear to provide any additional effectiveness in comparison with bDMARD monotherapy. Certolizumab pegol appeared possibly more effective than infliximab without adjusting for discontinuations, whereas golimumab was possibly more effective than infliximab after the aforementioned adjustment, which implies differences in treatment survival. The treatment response to TNF inhibitors used as the second and
FIG. 2 Proportional odds ratio for reaching EULAR response on TNF inhibitors as the patients' first biologic DMARD
The results of ordinal logistic regression analyses on reaching moderate or good EULAR treatment response on TNF inhibitors within 6 months after the first biologic DMARD onset. bDMARD: biologic DMARD; csDMARDs: conventional synthetic DMARDs; pOR: proportional odds ratio.
third bDMARDs was inferior compared with when they were used as the first bDMARD treatment. Oral glucocorticoid use seemed to improve the treatment response, but this effect diminished after adjusting for confounding factors, probably because glucocorticoids are prescribed for patients with higher baseline disease activity.
Ineligibility for the RCTs in our study was most often attributable to insufficient disease activity at baseline. Relatively few patients would have been excluded owing to their co-morbidities because many of the exclusion criteria used in RCTs related to hepatitis, for example, apply in routine care as well. The eligible patients generally had more severe disease in comparison with non-eligible patients on most of the disease activity measures used in our study. It could be argued that the inclusion criteria related to the activity of the rheumatic disease for RCTs are too stringent, considering that their results are directly generalizable to only a fraction of real-world patients. In Finland, the threshold for initiating bDMARD therapy has lowered during the past 15 years, and a greater proportion patients treated in the early 2000s would have been eligible for the RCTs than in 2014. Regretfully, we were not able to use all of the inclusion criteria of the RCTs owing to the excessive amount of missing data in morning stiffness and anti-CCP measurements. Lacking the 66/68 joint counts, we approximated them from 54/53 joint counts, which we believe to be a reasonably good estimation, albeit one that has not been validated. We did not exclude patients using the laboratory criteria on liver function or cell concentrations criteria from RCTs. Furthermore, the exclusion criteria for some RCTs were not reported at all or were too vague to be considered in our analyses. We also did not consider concomitant or prior csDMARD therapies as an inclusion criterion. Had we done so, the proportion of potentially eligible patients would probably have been even lower, because the use of csDMARDs and their combinations is strongly endorsed in Finland. Although the inclusion criteria of several early RCTs do not mention prior bDMARD treatment, it is very unlikely that patients enrolled in an RCT in 1999 would have had any previous experience with bDMARDs.
The eligible patients achieved an ACR50 response 1.6 times more often than the non-eligible patients. A similar trend has been observed in previous studies [3, 6], but our study was the first to include certolizumab pegol and golimumab in such a comparison. According to the pooled results, the efficacy measured in RCTs was comparable to the effectiveness observed among the real-world patients potentially eligible for them. More modest effectiveness can be expected for the non-eligible patients, although many of them still benefited from the treatment. The difference in treatment responses between patients eligible and not eligible for RCTs was most probably mediated by the differences in disease activity at baseline. Consequently, the non-eligible patients were more likely to reach DAS28 remission compared with their eligible counterparts by having a lower DAS28 score initially. The patients eligible for RCTs were older and had a longer time from diagnosis and more erosions in comparison with the non-eligible patients. We hypothesized that the treatment response and remission criteria comprising swollen and tender joint counts could be less sensitive for the patients with prolonged and erosive disease. If this were to be the case, the difference in treatment responses between the eligible and non-eligible patients could be even greater than our results indicate. The seven statistically significant comparisons in ACR50 response between eligible and non-eligible patients all featured either etanercept or adalimumab as the intervention, but a similar trend was observed across all TNF inhibitors. Similar treatment responses were observed between RCTs and routine care patients eligible for them. However, comparing treatment responses measured in RCTs and observational studies is not straightforward because there might be many unreported differences in patient characteristics, not to mention the dissimilar follow-up procedures. At 6 months, 14% of the users of the first bDMARD had been lost to follow-up. In addition, 22% of the patients discontinued the treatment within the first 6 months for various reasons, including lack of treatment response and adverse events. Regardless of the reason for discontinuation, we treated all discontinuers and patients lost to follow-up as non-responders in LUNDEX-adjusted sensitivity analyses. In truth, however, not all patients lost to follow-up discontinued the treatment and, as a result, the true effectiveness lies somewhere between the base case and LUNDEX-adjusted results. Missing data are often an issue in observational studies, but with multiple imputation we took the uncertainty caused by it into account. We excluded nearly one-quarter of the medication periods owing to the lack of reliable baseline visit, but this was necessary to ensure the validity of the effectiveness measurements. ROB-FIN did not collect data on patients' prior medication data until recently; hence, these data were not available for the present study. Regardless, a recent survey study found that 95% of Finnish RA patients treated with self-injectable bDMARDs are being or have previously been treated with MTX [40] .
To summarize, different TNF inhibitors were mostly equipotent in routine clinical practice, but MTX co-therapy improved the treatment response over TNF-inhibitor monotherapy, perhaps owing to a lower presence of anti-drug antibodies to TNF inhibitors in MTX-treated patients. The efficacy of TNF inhibitors measured in RCTs cannot be generalized directly into Finnish routine health care because only 7.644% of the patients were potentially eligible for RCTs, and the eligible patients had better treatment responses compared with the non-eligible patients. 
